• search

Malaria drug plant to boost agro-economy

Written by: Staff

Kharagpur, Aug 19: Artemisisin, an anti-malarial drug, will now not only improve health but also enhance the rural economy through value chain improvement.

Talking to the sources, Director of Central Institute of Medicinal and Aromatic Plants (CIMAP) S P S Khanuja said, farmers growing the anti-malarial drug plant variety, Artemisia annua, will earn more than Rs 70,000 per hectare in seven months.

'' This crop is easy to cultivate. It can be grown with other food crops thus increasing the earning capacity of the farmers,'' Dr Khanuja said, adding that CIMAP is at present working to find an higher alternative for the drug.

Dr Khanuja, who received the Nina Saxena Excellence in Technology Award here yesterday for the invention of this plant, said this would help eradicate cerebral malaria caused by Plasmodim falciparum.

''I believe Artemisisin will eradicate malaria from the developing world, where over two billion people are affected and one million die every year with this disease,'' he said.

The drug, which was earlier imported from China, is available in most of the pharmacies across the country as Emal.

''Our team has created a super genotype of the Chinese plant through molecular genetics,'' Dr Khanuja said, adding that this is the first genotype drug yielding plant through molecular breeding.

The Artemisisin content of the plant is as high as 1.05 per cent or 15,000 kg.

CIMAP had given licence to seven pharma companies like Themis and ICAP to have agreement with the farmers for assured price cultivation over an area of 2000 acres in North India initially, the director added.


For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more